Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andreas Villunger is active.

Publication


Featured researches published by Andreas Villunger.


Cell Death & Differentiation | 2007

How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?

A Olsson; Claudia Manzl; Andreas Strasser; Andreas Villunger

A number of elegant studies exploring the consequences of expression of various mutant forms of p53 in mice have been published over the last years. The results and conclusions drawn from these studies often contradict results previously obtained in biochemical assays and cell biology studies, questioning their relevance for p53 function in vivo. Owing to the multitude of post-translational modifications imposed on p53, however, the in vivo validation of their relevance for proper protein function and tumour suppression is constantly lagging behind new biochemical discoveries. Nevertheless, mouse genetics presents again its enormous power. Despite being relatively slow and tedious, it has become indispensable for researchers to sort out the wheat from the chaff in an endless sea of publications on p53.


Cell Death & Differentiation | 2006

BH3-only proteins in cell death initiation, malignant disease and anticancer therapy

Verena Labi; M Erlacher; S Kiessling; Andreas Villunger

Induction of apoptosis in tumour cells, either by direct activation of the death receptor pathway using agonistic antibodies or recombinant ligands, or direct triggering of the Bcl-2-regulated intrinsic apoptosis pathway by small molecule drugs, carries high hopes to overcome the shortcomings of current anticancer therapies. The latter therapy concept builds on a more detailed understanding of how Bcl-2-like molecules maintain mitochondrial integrity and how BH3-only proteins and Bax/Bak-like molecules can undermine it. Means to unleash the apoptotic potential of BH3-only proteins in tumour cells, or bypass the need for BH3-only proteins by blocking possible interactions of Bcl-2-like prosurvival molecules with Bax and/or Bak allowing their direct activation, constitute interesting options for the design of novel anticancer therapies.


Cell Death & Differentiation | 2008

In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute

Ewa M. Michalak; Andreas Villunger; Jerry M. Adams; Andreas Strasser

The ability of p53 to induce apoptosis in cells with damaged DNA is thought to contribute greatly to its tumour suppressor function. P53 has been proposed to induce apoptosis via numerous transcriptional targets or even by direct cytoplasmic action. Two transcriptional targets shown to mediate its apoptotic role in several cell types encode Noxa and Puma, BH3-only members of the Bcl-2 family. To test if their functions in p53-dependent apoptosis overlap, we generated mice lacking both. These mice develop normally and no tumours have yet arisen. In embryonic fibroblasts, the absence of both Noxa and Puma prevented induction of apoptosis by etoposide. Moreover, following whole body γ-irradiation, the loss of both proteins protected thymocytes better than loss of Puma alone. Indeed, their combined deficiency protected thymocytes as strongly as loss of p53 itself. These results indicate that, at least in fibroblasts and thymocytes, p53-induced apoptosis proceeds principally via Noxa and Puma, with Puma having the predominant role in diverse cell types. The absence of tumours in the mice suggests that tumour suppression by p53 requires functions in addition to induction of apoptosis.


Journal of Immunology | 2000

Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD

Andreas Villunger; David C. S. Huang; Nils Holler; Juerg Tschopp; Andreas Strasser

Jun kinase signaling can be elicited by death receptor activation, but the mechanism and significance of this event are still unclear. It has been reported that cross-linking Abs to Fas trigger c-Jun N-terminal kinase (JNK) signaling via caspase-mediated activation of MEKK1 (JNK kinase kinase), elevation of ceramide levels or by recruitment of death domain associated protein (DAXX) to Fas. The effect of physiological ligand for Fas on JNK signaling was never investigated, although evidence is accumulating that Fas ligand is able to induce cellular responses distinct from those evoked by Ab-mediated cross-linking of Fas. Therefore, we investigated the effect of Fas ligand on JNK signaling. Like its ability to induce cell death, Fas ligand reliably activated JNK only upon extensive aggregation of the receptor. Although this was partially dependent on caspase activation, DAXX was not required. DAXX and other death receptor-associated proteins, which have been reported to bind directly or indirectly to Fas, such as receptor interacting protein (RIP) and RIP-associated ICH-1/CED-3-homologous protein with a death domain (RAIDD), were shown to be dispensable for Fas ligand-induced apoptosis.


The Journal of Neuroscience | 2006

BH3-only proapoptotic Bcl-2 family members noxa and puma mediate neural precursor cell death

Rizwan S. Akhtar; Ying Geng; Barbara J. Klocke; Cecelia B. Latham; Andreas Villunger; Ewa M. Michalak; Andreas Strasser; Steven L. Carroll; Kevin A. Roth

Neural precursor cells (NPCs) are highly sensitive to genotoxic injury, which triggers activation of the intrinsic mitochondria-dependent apoptotic pathway. This pathway is typically initiated by members of the BH3 (Bcl-2 homology 3)-only subgroup of the Bcl-2 (B-cell CLL/lymphoma 2) protein family, which are positioned upstream in the apoptotic pathway to respond to specific death stimuli. We have shown previously that NPCs deficient in the tumor suppressor protein p53 show significantly less death after exposure to genotoxic injury or to staurosporine (STS), a broad kinase inhibitor and potent apoptosis inducer. p53 has been shown to regulate the expression of both Noxa and Puma, two BH3-only proteins, although their involvement in p53-dependent cell death appears to be cell-type and stimulus specific. A systematic comparison of the relative contributions of Noxa and Puma to NPC apoptosis has not yet been performed. We hypothesized that p53-dependent transcription of Noxa and Puma leads to death in telencephalic NPCs exposed to genotoxic stress. We found that genotoxic injury induces a rapid p53-dependent increase in expression of Noxa and Puma mRNA in telencephalic NPCs. Furthermore, deficiency of either Noxa or Puma inhibited DNA damage-induced caspase-3 activation and cell death in telencephalic NPCs in vitro. However, only Puma deficiency protected telencephalic ventricular zone NPCs from death in vivo. In contrast to genotoxic injury, STS produced a p53-independent increase in Noxa and Puma expression, but neither Noxa nor Puma was required for STS-induced NPC death. Together, these experiments identify Noxa and Puma as important regulators of genotoxin-induced telencephalic NPC death.


Nature Medicine | 1999

The great escape: Is immune evasion required for tumor progression?

Andreas Villunger; Andreas Strasser

A study on page 938 reports the identification of an ovarian and uterine tumor-associated ligand, RCAS1, which inhibits growth of activated T lymphocytes.


Cancer Cell | 2005

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

Ting Ting Tan; Kurt Degenhardt; Deirdre A. Nelson; Brian Beaudoin; Wilberto Nieves-Neira; Andreas Villunger; Jerry M. Adams; Eileen White


Cold Spring Harbor Symposia on Quantitative Biology | 2005

Subversion of the Bcl-2 life/death switch in cancer development and therapy.

Jerry M. Adams; David C. S. Huang; Andreas Strasser; Simon N. Willis; Lin Chen; Andrew Wei; M. Van Delft; Jamie I. Fletcher; Junya Kuroda; Ewa M. Michalak; Priscilla N. Kelly; Andreas Villunger; Lorraine A. O'Reilly; Mary L. Bath; Darrin P. Smith; Alexander Egle; Alan W. Harris; Mark G. Hinds; Peter M. Colman; Suzanne Cory


Nature Immunology | 2003

Efficient T cell receptor-mediated apoptosis in nonobese diabetic mouse thymocytes.

Andreas Villunger; Vanessa S. Marsden; Andreas Strasser


Oncology Research | 1998

Does death receptor signaling play a role in tumorigenesis and cancer therapy

Andreas Villunger; Andreas Strasser

Collaboration


Dive into the Andreas Villunger's collaboration.

Top Co-Authors

Avatar

Andreas Strasser

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Andreas Strasser

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Jerry M. Adams

Brookdale University Hospital and Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ewa M. Michalak

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Verena Labi

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

David C. S. Huang

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leigh Coultas

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Priscilla N. Kelly

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Miriam Erlacher

University Medical Center Freiburg

View shared research outputs
Researchain Logo
Decentralizing Knowledge